JP5608091B2 - 抗メソセリン抗体およびその使用 - Google Patents

抗メソセリン抗体およびその使用 Download PDF

Info

Publication number
JP5608091B2
JP5608091B2 JP2010535269A JP2010535269A JP5608091B2 JP 5608091 B2 JP5608091 B2 JP 5608091B2 JP 2010535269 A JP2010535269 A JP 2010535269A JP 2010535269 A JP2010535269 A JP 2010535269A JP 5608091 B2 JP5608091 B2 JP 5608091B2
Authority
JP
Japan
Prior art keywords
antibody
seq
mesothelin
dna
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010535269A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011504372A (ja
Inventor
アントイェ・カーネルト
デイビッド・ライト
ダグ・シュナイダー
レナート・パリー
昇 里澤
タラ・レネー・ヘイトネル・ハンセン
シュテファン・シュタイトル
ウルリケ・シューベルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Property GmbH filed Critical Bayer Intellectual Property GmbH
Publication of JP2011504372A publication Critical patent/JP2011504372A/ja
Application granted granted Critical
Publication of JP5608091B2 publication Critical patent/JP5608091B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010535269A 2007-11-26 2008-11-19 抗メソセリン抗体およびその使用 Expired - Fee Related JP5608091B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US437807P 2007-11-26 2007-11-26
US61/004,378 2007-11-26
PCT/EP2008/009756 WO2009068204A1 (en) 2007-11-26 2008-11-19 Anti-mesothelin antibodies and uses therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014137893A Division JP2014221064A (ja) 2007-11-26 2014-07-03 抗メソセリン抗体およびその使用

Publications (2)

Publication Number Publication Date
JP2011504372A JP2011504372A (ja) 2011-02-10
JP5608091B2 true JP5608091B2 (ja) 2014-10-15

Family

ID=40351874

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010535269A Expired - Fee Related JP5608091B2 (ja) 2007-11-26 2008-11-19 抗メソセリン抗体およびその使用
JP2014137893A Pending JP2014221064A (ja) 2007-11-26 2014-07-03 抗メソセリン抗体およびその使用
JP2018038254A Expired - Fee Related JP6717869B2 (ja) 2007-11-26 2018-03-05 抗メソセリン抗体およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014137893A Pending JP2014221064A (ja) 2007-11-26 2014-07-03 抗メソセリン抗体およびその使用
JP2018038254A Expired - Fee Related JP6717869B2 (ja) 2007-11-26 2018-03-05 抗メソセリン抗体およびその使用

Country Status (30)

Country Link
US (3) US9023351B2 (enExample)
EP (3) EP2634196A1 (enExample)
JP (3) JP5608091B2 (enExample)
KR (1) KR101559599B1 (enExample)
CN (2) CN104151429B (enExample)
AU (1) AU2008329221B2 (enExample)
BR (1) BRPI0819909B8 (enExample)
CA (1) CA2706529C (enExample)
CO (1) CO6280409A2 (enExample)
CR (1) CR11456A (enExample)
CU (1) CU23833A3 (enExample)
CY (1) CY1117437T1 (enExample)
DK (1) DK2215121T3 (enExample)
DO (1) DOP2010000150A (enExample)
EC (1) ECSP10010191A (enExample)
ES (1) ES2569513T3 (enExample)
GT (1) GT201000148A (enExample)
HN (1) HN2010001062A (enExample)
HR (1) HRP20160485T1 (enExample)
HU (1) HUE027358T2 (enExample)
IL (1) IL205681A0 (enExample)
MA (1) MA31862B1 (enExample)
MX (1) MX2010005603A (enExample)
MY (1) MY157164A (enExample)
NZ (1) NZ585551A (enExample)
PL (1) PL2215121T3 (enExample)
SI (1) SI2215121T1 (enExample)
TN (1) TN2010000234A1 (enExample)
UA (1) UA106036C2 (enExample)
WO (1) WO2009068204A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014221064A (ja) * 2007-11-26 2014-11-27 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 抗メソセリン抗体およびその使用

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2700860C (en) * 2007-10-01 2016-07-19 Jonathan A. Terrett Human antibodies that bind mesothelin, and uses thereof
UY32560A (es) * 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
WO2012087962A2 (en) * 2010-12-20 2012-06-28 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
US9402916B2 (en) 2011-03-17 2016-08-02 The University Of Birmingham Re-directed immunotherapy
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
AU2012244673A1 (en) 2011-04-21 2013-11-28 Seattle Genetics, Inc. Novel binder-drug conjugates (ADCs) and their use
WO2014004549A2 (en) * 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
JP6307085B2 (ja) * 2012-09-27 2018-04-04 ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンテッド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズＴｈｅ Ｕｎｉｔｅｄ Ｓｔａｔｅｓ ｏｆ Ａｍｅｒｉｃａ，ａｓ ｒｅｐｒｅｓｅｎｔｅｄ ｂｙ ｔｈｅ Ｓｅｃｒｅｔａｒｙ，Ｄｅｐａｒｔｍｅｎｔ ｏｆ Ｈｅａｌｔｈ ａｎｄ Ｈｕｍａｎ Ｓｅｒｖｉｃｅｓ メソテリン抗体および強力な抗腫瘍活性を惹起するための方法
CN103819559B (zh) * 2013-12-10 2016-02-24 中国科学院武汉病毒研究所 一种抗间皮素纳米抗体及其编码基因和该纳米抗体的用途
CN106163568B (zh) 2013-12-23 2021-03-23 拜耳制药股份公司 含纺锤体驱动蛋白（ksp）的抗体药物偶联物（adc）
AU2015326911C1 (en) 2014-09-30 2025-12-18 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (DPRs) antibody
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
MX2017014822A (es) 2015-05-18 2018-04-30 Tcr2 Therapeutics Inc Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
EP3310440A1 (de) 2015-06-22 2018-04-25 Bayer Pharma Aktiengesellschaft Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren gruppen
US20180193456A1 (en) * 2015-06-30 2018-07-12 Henlius Biotech Co., Ltd. Anti-vascular endothelial growth factor receptor 2 (vegfr2) antibodies
US10793641B2 (en) * 2015-08-21 2020-10-06 Carsgen Therapeutics Co., Ltd. Fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin
KR101782487B1 (ko) 2015-09-24 2017-09-27 재단법인 목암생명과학연구소 신규 항-메소텔린 항체 및 이를 포함하는 조성물
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
US11413340B2 (en) 2015-12-22 2022-08-16 Novartis Ag Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
CN109072195A (zh) 2015-12-30 2018-12-21 诺华股份有限公司 具有增强功效的免疫效应细胞疗法
WO2017141604A1 (ja) 2016-02-15 2017-08-24 地方独立行政法人神奈川県立病院機構 膜型ムチン様タンパク質の認識とその医療応用
WO2017149515A1 (en) 2016-03-04 2017-09-08 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
JP7251981B2 (ja) 2016-03-24 2023-04-04 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂基を有する細胞毒性活性剤のプロドラッグ
CN109715808A (zh) 2016-04-15 2019-05-03 诺华股份有限公司 用于选择性蛋白质表达的组合物和方法
SG11201810591VA (en) 2016-05-27 2018-12-28 Abbvie Biotherapeutics Inc Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
JP7022707B2 (ja) 2016-06-15 2022-02-18 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤および抗ｃｄ１２３抗体を含む特異的抗体－薬物－コンジュゲート（ａｄｃ）
TW201831513A (zh) 2016-06-20 2018-09-01 Ｆ星貝塔有限公司 結合物件(一)
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
CN110267677A (zh) 2016-08-01 2019-09-20 诺华股份有限公司 使用与原m2巨噬细胞分子抑制剂组合的嵌合抗原受体治疗癌症
CA3032498A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
US20190218294A1 (en) 2016-09-09 2019-07-18 Bristol-Myers Squibb Company Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
MX2019003899A (es) 2016-10-07 2019-08-14 Tcr2 Therapeutics Inc Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion.
EP3544996A2 (en) 2016-11-22 2019-10-02 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
FI3548515T3 (fi) 2016-12-01 2026-03-04 Regeneron Pharma Radioleimattuja anti-PD-L1-vasta-aineita immuno-PET-kuvantamiseen
US12059472B2 (en) 2016-12-21 2024-08-13 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
EP3558387B1 (de) 2016-12-21 2021-10-20 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
PE20191235A1 (es) 2016-12-21 2019-09-11 Bayer Pharma AG Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente
EP3574005B1 (en) 2017-01-26 2021-12-15 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
EP3638295A1 (en) 2017-06-13 2020-04-22 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
JP6339283B1 (ja) 2017-10-31 2018-06-06 国立大学法人 岡山大学 Ｄｎａ、ポリペプチド、抗メソセリン抗体、腫瘍イメージング剤及び複合体
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
AU2018387741B2 (en) 2017-12-19 2025-09-25 Invox Pharma Limited FC binding fragments comprising a PD-L1 antigen-binding site
WO2019124468A1 (ja) * 2017-12-24 2019-06-27 ノイルイミューン・バイオテック株式会社 ヒトメソセリンを特異的に認識する細胞表面分子、ｉｌ－７、及びｃｃｌ１９を発現する免疫担当細胞
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
CA3097872A1 (en) 2018-04-27 2019-10-31 Biogen Ma Inc. Human-derived anti-(poly-ga) dipeptide repeat (dpr) antibody
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
US12344672B2 (en) 2018-07-12 2025-07-01 Invox Pharma Limited Antibody molecules that bind PD-L1 and CD137
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
MX2021000399A (es) 2018-07-12 2021-05-27 F Star Therapeutics Ltd Moleculas de anticuerpo que se unen a cd137 y ox40.
CN109053882B (zh) * 2018-08-28 2019-08-23 东莞市朋志生物科技有限公司 一种ns1蛋白的结合蛋白以及应用
TW202026006A (zh) 2018-08-30 2020-07-16 美商Ｔｃｒ２療法股份有限公司 使用融合蛋白進行tcr再程式化之組成物及方法
CA3120800A1 (en) 2018-12-17 2020-06-25 Revitope Limited Twin immune cell engager
MX2021007392A (es) 2018-12-20 2021-08-24 Novartis Ag Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
WO2020165834A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
BR112021015783A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
US20220135658A1 (en) * 2019-03-14 2022-05-05 Morphosys Ag Antibodies targeting c5ar
EP3941503A1 (en) 2019-03-19 2022-01-26 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
WO2020234114A1 (en) 2019-05-21 2020-11-26 Bayer Aktiengesellschaft A novel stable high concentration formulation for anetumab ravtansine
EP4004040A4 (en) * 2019-07-29 2023-08-16 Fred Hutchinson Cancer Center METHODS AND COMPOSITIONS FOR INDUCING NOTCH SIGNALING IN TUMOR MICROOM ENVIRONMENTS
AU2020405230A1 (en) 2019-12-20 2022-06-23 Amgen Inc. Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors
TW202135859A (zh) 2019-12-20 2021-10-01 瑞士商諾華公司 組合療法
EP4121454A1 (en) * 2020-03-19 2023-01-25 Imperial College Innovations Limited Coronavirus antibody
KR20230024967A (ko) 2020-06-11 2023-02-21 노파르티스 아게 Zbtb32 억제제 및 이의 용도
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
JP7819176B2 (ja) 2020-08-03 2026-02-24 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CN116063527A (zh) * 2021-09-30 2023-05-05 南京北恒生物科技有限公司 靶向间皮素的抗体及其用途
TW202321296A (zh) 2021-10-06 2023-06-01 美商鏈接免疫療法公司 抗間皮素抗原結合分子及其用途
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
JP2025529210A (ja) 2022-09-01 2025-09-04 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド アポリポタンパク質ｌ１を導いて哺乳動物の細胞死を誘導するための組成物及び方法
IL320482A (en) 2022-10-25 2025-06-01 Peptomyc S L Combination therapy for cancer treatment
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
CN116019939A (zh) * 2022-11-24 2023-04-28 华中科技大学同济医学院附属协和医院 靶向msln的分子探针以及用途
WO2024119065A2 (en) * 2022-12-02 2024-06-06 Jecho Laboratories, Inc. Anti-mesothelin bispecific antibodies and methods of use
WO2024226827A2 (en) 2023-04-25 2024-10-31 Arsenal Biosciences, Inc. Novel receptors for transcription regulation
TW202500126A (zh) 2023-05-24 2025-01-01 美商金橘生物科技公司 雜環化合物及其用途
WO2024251846A1 (en) 2023-06-07 2024-12-12 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with mek inhibitors for the treatment of cancer
EP4473974A1 (en) 2023-06-07 2024-12-11 Peptomyc, S.L. Omomyc and kras inhibitors combination therapy for the treatment of cancer
TW202502371A (zh) 2023-06-07 2025-01-16 瓦爾希伯倫私人腫瘤研究基金會 用於治療癌症的與ｂｒａｆ抑制劑的組合療法
CN117659133B (zh) * 2023-12-06 2024-09-20 南京鼓楼医院 间皮素靶向结合蛋白、其编码核酸以及用途
CN117843793B (zh) * 2024-03-07 2024-07-09 深圳真实生物医药科技有限公司 抗间皮素抗体、抗原结合片段及其用途
WO2025235862A1 (en) 2024-05-10 2025-11-13 Inndura Therapeutics Inc. A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
AU703769B2 (en) 1996-01-05 1999-04-01 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Mesothelium antigen and methods and kits for targeting it
US6809184B1 (en) * 1997-12-01 2004-10-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
CA2318576C (en) * 1997-12-01 2009-04-14 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Antibodies, including fv molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
DE60028361T2 (de) * 1999-02-26 2007-05-10 Pacific Northwest Research Institute, Seattle Verfahren und zusammensetzungen zur karzinomdiagnose
AU781396B2 (en) 1999-07-20 2005-05-19 Morphosys Ag Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
EP1861425B1 (en) 2005-03-10 2012-05-16 Morphotek, Inc. Anti-mesothelin antibodies
EP1885758A2 (en) * 2005-05-12 2008-02-13 The Government of the United States of America as Represented by The Department of Health and Human Services Anti-mesothelin antibodies useful for immunological assays
PT1888643E (pt) 2005-05-18 2015-01-14 Morphosys Ag Anticorpos anti-fec-gm e as respectivas utilizações
US20070014720A1 (en) * 2005-06-02 2007-01-18 Gadi Gazit-Bornstein Antibodies directed to CD20 and uses thereof
CA2700860C (en) * 2007-10-01 2016-07-19 Jonathan A. Terrett Human antibodies that bind mesothelin, and uses thereof
CN104151429B (zh) * 2007-11-26 2018-07-10 拜耳知识产权有限责任公司 抗-间皮素抗体及其用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014221064A (ja) * 2007-11-26 2014-11-27 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 抗メソセリン抗体およびその使用

Also Published As

Publication number Publication date
HK1200856A1 (en) 2015-08-14
BRPI0819909B8 (pt) 2021-05-25
BRPI0819909A2 (pt) 2017-12-19
EP3103814A1 (en) 2016-12-14
HRP20160485T1 (hr) 2016-06-03
EP2634196A1 (en) 2013-09-04
ES2569513T3 (es) 2016-05-11
CY1117437T1 (el) 2017-04-26
KR101559599B1 (ko) 2015-10-12
US20150259433A1 (en) 2015-09-17
AU2008329221A1 (en) 2009-06-04
BRPI0819909B1 (pt) 2021-04-20
HUE027358T2 (en) 2016-09-28
MX2010005603A (es) 2010-08-02
US9023351B2 (en) 2015-05-05
HN2010001062A (es) 2013-10-07
NZ585551A (en) 2012-06-29
IL205681A0 (en) 2010-11-30
EP2215121A1 (en) 2010-08-11
JP6717869B2 (ja) 2020-07-08
CN101952319B (zh) 2015-04-15
MY157164A (en) 2016-05-13
CN101952319A (zh) 2011-01-19
DOP2010000150A (es) 2010-09-15
CN104151429B (zh) 2018-07-10
SI2215121T1 (sl) 2016-06-30
GT201000148A (es) 2014-04-03
HK1148541A1 (en) 2011-09-09
EP2215121B1 (en) 2016-02-10
UA106036C2 (uk) 2014-07-25
JP2014221064A (ja) 2014-11-27
DK2215121T3 (en) 2016-05-02
KR20100097660A (ko) 2010-09-03
CA2706529C (en) 2016-10-25
JP2011504372A (ja) 2011-02-10
ECSP10010191A (es) 2010-07-30
WO2009068204A1 (en) 2009-06-04
CR11456A (es) 2010-11-12
PL2215121T3 (pl) 2016-07-29
CO6280409A2 (es) 2011-05-20
AU2008329221B2 (en) 2013-11-07
CU23833A3 (es) 2012-10-15
JP2018102311A (ja) 2018-07-05
TN2010000234A1 (en) 2011-11-11
CN104151429A (zh) 2014-11-19
US20110027268A1 (en) 2011-02-03
CA2706529A1 (en) 2009-06-04
US20180258181A1 (en) 2018-09-13
MA31862B1 (fr) 2010-11-01

Similar Documents

Publication Publication Date Title
JP5608091B2 (ja) 抗メソセリン抗体およびその使用
AU2016233495B2 (en) Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
CN107236043B (zh) 在体内具有抗肿瘤活性的抗人trop-2抗体
JP4869074B2 (ja) 抗体
EP3741777A1 (en) Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
JP2020515251A (ja) Ｂ７−ｈ３抗体、その抗原結合フラグメント、及びそれらの医学的使用
KR102405278B1 (ko) Alk7 결합 단백질 및 이들의 용도
US9676846B2 (en) Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US20240043568A1 (en) Development of new tumor engager therapeutic drug and use thereof
CN113227148B (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
JP2024500512A (ja) 抗ｂ７－ｈ３抗体およびその使用
RU2534890C2 (ru) Антитела против mst1r и их применение
HK1200856B (en) Anti-mesothelin antibodies and uses therefor
HK1148541B (en) Anti-mesothelin antibodies and uses therefor
HK40049006A (en) Anti-gpc3 antibody, antigen-binding fragment thereof, and medical use thereof
HK40049006B (en) Anti-gpc3 antibody, antigen-binding fragment thereof, and medical use thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110825

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20130321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140703

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140801

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140819

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140829

R150 Certificate of patent or registration of utility model

Ref document number: 5608091

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees